P911

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination With Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results From the Phase 1b MonumenTAL-2 Study

Emma Searle[1], Hang Quach[2], Noa Biran[3], Aurore Perrot[4], Jesus G Berdeja[5], Kathleen Dorritie[6], Catharina Van Elssen[7], Cyrille Touzeau[8], Sébastien Anguille[9], Deeksha Vishwamitra[10], Ashley Nguyen[10], Debopriya Ghosh[11], Elizabeth Shearin[10], Gary E Mason[10], Thomas Renaud[11], Jeffrey Matous[12]

[1]The Christie NHS Foundation Trust and the University of Manchester, Manchester, UK; [2]University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia; [3]Hackensack University Medical Center, Hackensack, NJ, USA; [4]Centre Hospitalier Universitaire de Toulouse, Oncopole, Toulouse, France; [5]Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN, USA; [6]UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; [7]Maastricht University Medical Centre, Maastricht, Netherlands; [8]Centre Hospitalier Universitaire de Nantes, Nantes, France; [9]Antwerp University Hospital, Edegem, Belgium; [10]Janssen Research & Development, Spring House, PA, USA; [11]Janssen Research & Development, Raritan, NJ, USA; [12]Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO, USA

Key Takeaway

With longer follow-up, tal + pom showed promising efficacy and a manageable safety profile consistent with previously reported analyses, which further supports tal as a versatile combination partner in RRMM

Conclusions

- Tal + pom showed rapid, deep, and durable responses; a trend for longer DOR with deeper response was observed, which suggests that pts with a ≥VGPR may have more durable responses
- Neutropenia was worse with the combination than with tal monotherapy, but its frequency was comparable to pom monotherapy[4,6,8]; there was no evidence of additive hematologic or CRS toxicities
- Similar rates of GPRC5D-related AEs were observed as with tal monotherapy, and the majority were grade 1/2, with few discontinuations[4]; dose reductions were used to manage AEs

Please scan QR code

Poster

https://www.congresshub.com/Oncology/EHA2024/Talquetamab/Searle

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

Acknowledgments
This study was funded by Janssen Research & Development, LLC. Medical writing support was provided by Alana Dorfstatter, PharmD, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC.

Disclosures
ES has served in a consulting role for Sanofi and Shattuck Labs; and has received honoraria from AbbVie and Janssen.

Introduction

- Talquetamab (tal) is the first approved G protein–coupled receptor family C group 5 member D (GPRC5D)-targeting bispecific antibody (BsAb) for the treatment of patients (pts) with relapsed/refractory multiple myeloma (RRMM)[1-3]
  - In the phase 1/2 MonumenTAL-1 study, tal showed overall response rates (ORRs) of >71% and a clinically manageable safety profile in pts with RRMM[4]
- Pomalidomide (pom), an established immunomodulatory drug, has direct on-tumor apoptotic activity and enhances immune activity[5,6]
- Initial MonumenTAL-2 results (clinical cut-off date: Oct 2023) showed that the combination of tal + pom led to rapid and deep responses in pts with RRMM[7]
- We report updated safety and efficacy results of tal + pom from MonumenTAL-2

Methods

- MonumenTAL-2 (NCT05050097) is a multiarm, phase 1b study of tal in combination with antimyeloma agents in pts with multiple myeloma
- The tal + pom treatment arm enrolled pts who were either naïve or exposed to prior T-cell redirection therapy (TCR) or pom (**Figure 1**)

Figure 1: MonumenTAL-2 (tal + pom) phase 1b study design



[a]With 2–3 step-up doses. [b]AEs assessed per CTCAE v5.0, except for CRS and ICANS, which were graded per ASTCT guidelines. [c]Assessed per IMWG 2016 criteria.
AE, adverse event; ASTCT, American Society for Transplantation and Cellular Therapy; CAR-T, chimeric antigen receptor-T cell; CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ICANS, immune effector cell–associated neurotoxicity syndrome; IMWG, International Myeloma Working Group; LOT, line of therapy; PFS, progression-free survival; PI, proteasome inhibitor; PO, by mouth; Q2W, every other week; QW, weekly, SC, subcutaneous.

Results

Baseline characteristics

- Baseline characteristics have been published previously[7]
- Briefly, the median age was 65.0 years, 39.1% of pts had high-risk cytogenetics, and 14.3% had extramedullary disease
- Prior treatments included CAR-T (8.6%), BsAb (2.9%), anti-CD38 antibody (74.3%), and pom (22.9%)

Efficacy

- As of April 22, 2024, ORR was 88.6% (**Figure 2**); additional efficacy outcomes are presented in **Table 1**
- High ORRs were observed in subgroups, including high-risk cytogenetics (77.8%) and prior CAR-T (100%) or pom (100%)
- Although numbers are small, a trend for longer DOR with deeper response was observed (**Table 2**)
- Responses deepened over time (**Figure 3**)

Figure 2: ORR



CR, complete response; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.

Table 1: Efficacy outcomes

	Tal + pom (N=35)
Median follow-up (range), months	16.8 (1.2–25.1)
Median time to first response (range), months	1.1 (0.0–3.3)
Median DOR, months (95% CI)	NR (12.0–NE)
12-month DOR rate, % (95% CI)	74.4 (53.5–86.9)
Median PFS, months (95% CI)	NR (12.9–NE)
12-month PFS rate, % (95% CI)	72.6 (53.9–84.7)

NE, not estimable; NR, not reached.

Table 2: DOR by depth of best response

Depth of response	12-month DOR rate (95% CI), %
PR	0.0 (NE–NE) n=2
VGPR	78.8 (38.1–94.3) n=11
CR	80.4 (50.6–93.2) n=17

Safety

- The most common AEs were taste-related events, infections, and CRS (**Table 3**)
- Cytopenias were mostly grade 3/4 and generally limited to the first few cycles
- ICANS occurred in 3 pts; all were grade 1
- Taste-, skin-, nail-, and rash-related GPRC5D AEs were mainly grade 1/2, with few discontinuations
- 9 pts had AEs that led to treatment discontinuation
- AEs led to dose reduction of tal or pom in 37.1% and 48.6% of pts, respectively; 65.7% and 77.1% of pts skipped doses of tal and pom due to AEs, respectively
  - The most common AEs that led to dose reduction of pom included neutropenia, peripheral neuropathy, and fatigue
  - Dose reduction and schedule changes were used to manage AEs
- In pts with and without oral toxicities, weight loss was evident early but stabilized and improved over time; a more gradual trend of improvement was noted in pts with oral toxicities
- The most common infections were pneumonia, upper respiratory tract infections, and COVID-19; infections were mostly grade 1/2
  - First-onset infections generally occurred in the first few cycles of treatment
- Consistent with target expression, there was no reduction in total CD19+ B cells during treatment

Table 3: Hematologic and nonhematologic AEs

TEAE ≥25%, n (%)	All patients (N=35)	
	Any grade	Grade 3/4
Hematologic AEs		
Neutropenia	22 (62.9)	20 (57.1)
Anemia	13 (37.1)	9 (25.7)
Thrombocytopenia	10 (28.6)	7 (20.0)
Nonhematologic AEs		
Taste-related[a]	30 (85.7)	0
Infections	28 (80.0)	8 (22.9)
CRS	26 (74.3)	1 (2.9)
Skin-related[b]	26 (74.3)	2 (5.7)
Nail-related[c]	24 (68.6)	0
Dry mouth	19 (54.3)	0
Fatigue	19 (54.3)	5 (14.3)
Pyrexia	14 (40.0)	1 (2.9)
Nausea	13 (37.1)	0
Diarrhea	11 (31.4)	0
Headache	10 (28.6)	1 (2.9)
Rash-related[d]	10 (28.6)	1 (2.9)
Back pain	9 (25.7)	1 (2.9)
Cough	9 (25.7)	0
Weight decreased	9 (25.7)	2 (5.7)

[a]Includes dysgeusia, ageusia, taste disorder, and hypogeusia. Per CTCAE v5.0, the maximum grade of dysgeusia is 2. [b]Includes skin exfoliation, dry skin, pruritus, and palmar-plantar erythrodysesthesia syndrome. [c]Includes nail discoloration, nail disorder, nail toxicity, nail dystrophy, nail ridging, onychoclasis, onycholysis, and onychomadesis. [d]Includes rash, rash maculopopular, rash erythematous, and erythema.
TEAE, treatment-emergent adverse event.

Figure 3: Treatment response in pts who had ≥PR with tal + pom



Includes both confirmed and unconfirmed responses.
+, penta-refractory; D/C, discontinued; MR, minimal residual; PD, progressive disease; SD, stable disease; TR, triple-class refractory.

References
1. Verkleij CPM, et al. *Blood Adv* 2021;5:2196-215. 2. TALVEY™ (talquetamab-tgvs). Prescribing information. Horsham, PA: Janssen Biotech, Inc.; 2023. 3. European Medicines Agency. TALVEY™ (talquetamab). Accessed May 2, 2024. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/talvey. 4. Schinke C, et al. Presented at ASCO; June 2–6, 2023; Chicago, IL, USA & Virtual. #8036. 5. Bazarbachi AH, et al. *Leukemia* 2019;33:2243-357. 6. POMALYST® (pomalidomide). Prescribing information. Summit, NJ: Celgene Corporation; 2020. 7. Matous J, et al. Presented at ASH; December 10–13, 2023; San Diego, CA, USA. #1014. 8. Dimopoulos MA, et al. *Blood* 2016;128:497-503.

Multiple Myeloma

Presented by E Searle at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13–16, 2024; Madrid, Spain